• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.艾乐替尼在一名克唑替尼治疗进展且伴有弥漫性软脑膜癌病的ALK阳性非小细胞肺癌患者中诱导出持久（>15个月）的完全缓解。
Oncologist. 2015 Feb;20(2):224-6. doi: 10.1634/theoncologist.2014-0309. Epub 2015 Jan 7.
2
Alectinib Superior to Crizotinib for ALK+ NSCLC.阿来替尼优于克唑替尼用于治疗 ALK+ NSCLC。
Cancer Discov. 2017 Aug;7(8):OF5. doi: 10.1158/2159-8290.CD-NB2017-090. Epub 2017 Jun 9.
3
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.ALK 融合蛋白阳性非小细胞肺癌患者长期阿来替尼治疗后的脑膜转移。
Invest New Drugs. 2019 Feb;37(1):184-187. doi: 10.1007/s10637-018-0633-6. Epub 2018 Jul 3.
4
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.克唑替尼耐药的间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者中艾乐替尼针对全身疾病和脑转移的安全性和活性：一项 1/2 期研究剂量探索部分的结果。
Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.
5
ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.ALK 抑制剂克唑替尼联合鞘内注射甲氨蝶呤治疗非小细胞肺癌伴脑膜转移。
Lung Cancer. 2012 May;76(2):253-4. doi: 10.1016/j.lungcan.2012.02.003. Epub 2012 Mar 3.
6
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.选择性ALK抑制剂阿来替尼在携带G1269A突变的ALK阳性非小细胞肺癌细胞系中的抗肿瘤活性：阿来替尼对ALK G1269A突变细胞的疗效。
Cancer Chemother Pharmacol. 2016 Mar;77(3):623-8. doi: 10.1007/s00280-016-2977-y. Epub 2016 Feb 5.
7
The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.中枢神经系统作为 ALK 阳性非小细胞肺癌的庇护所。
J Thorac Oncol. 2013 Dec;8(12):1570-3. doi: 10.1097/JTO.0000000000000029.
8
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.下一代测序揭示了一种新型 NSCLC ALK F1174V 突变，并证实 ALK G1202R 突变使对克唑替尼治疗后进展的 ALK 重排 NSCLC 患者对艾乐替尼（CH5424802/RO5424802）具有高水平耐药性。
J Thorac Oncol. 2014 Apr;9(4):549-53. doi: 10.1097/JTO.0000000000000094.
9
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.ALK基因中I1171位点的二次突变赋予了对克唑替尼和阿来替尼的耐药性。
J Thorac Oncol. 2014 Dec;9(12):e86-7. doi: 10.1097/JTO.0000000000000358.
10
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.选择性ALK抑制剂阿来替尼在克唑替尼耐药模型中具有强大的抗肿瘤活性。
Cancer Lett. 2014 Sep 1;351(2):215-21. doi: 10.1016/j.canlet.2014.05.020. Epub 2014 Jun 2.

引用本文的文献

1
Leptomeningeal Disease: Current Approaches and Future Directions.柔脑膜疾病：当前方法与未来方向
Curr Neurol Neurosci Rep. 2025 Mar 18;25(1):25. doi: 10.1007/s11910-025-01412-y.
2
Brain metastases from lung cancer: recent advances and novel therapeutic opportunities.肺癌脑转移：最新进展与新型治疗机遇
Discov Oncol. 2025 Feb 11;16(1):157. doi: 10.1007/s12672-025-01873-0.
3
Radiotherapy and Systemic Treatment for Leptomeningeal Disease.柔脑膜疾病的放射治疗与全身治疗
Biomedicines. 2024 Aug 7;12(8):1792. doi: 10.3390/biomedicines12081792.
4
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.间变性淋巴瘤激酶（ALK）和ROS1重排肺癌的转移方式、潜在机制及当前可能的治疗策略
RSC Adv. 2019 Jun 7;9(31):17921-17932. doi: 10.1039/c9ra02258a. eCollection 2019 Jun 4.
5
A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer.培美曲塞鞘内注射联合全身治疗肺癌脑膜转移的回顾性研究。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221078429. doi: 10.1177/15330338221078429.
6
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches.实体瘤的软脑膜转移：诊断与分子方法的最新进展
Cancers (Basel). 2021 Jun 9;13(12):2888. doi: 10.3390/cancers13122888.
7
Kinase drug discovery 20 years after imatinib: progress and future directions.伊马替尼发现 20 年后的激酶药物研发：进展与未来方向
Nat Rev Drug Discov. 2021 Jul;20(7):551-569. doi: 10.1038/s41573-021-00195-4. Epub 2021 May 17.
8
Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis.阿来替尼和劳拉替尼通过调节非小细胞肺癌转移中的 EMT 相关蛋白和 MMPs 发挥作用。
Bosn J Basic Med Sci. 2021 Jun 1;21(3):331-338. doi: 10.17305/bjbms.2020.5066.
9
ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases.ALK-脑预后指数——ALK重排的非小细胞肺癌合并脑转移患者预后工具的初步研究
Cancers (Basel). 2020 Jul 6;12(7):1804. doi: 10.3390/cancers12071804.
10
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.洛拉替尼在既往治疗的 ALK 阳性非小细胞肺癌患者中的脑渗透：CNS 和非 CNS 进展的累积发生率与洛拉替尼相关。
Target Oncol. 2020 Feb;15(1):55-65. doi: 10.1007/s11523-020-00702-4.

本文引用的文献

1
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.阿来替尼可挽救先前接受过克唑替尼和色瑞替尼治疗的ALK阳性肺癌患者的中枢神经系统复发。
J Thorac Oncol. 2015 Feb;10(2):232-6. doi: 10.1097/JTO.0000000000000455.
2
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.克唑替尼对比化疗用于治疗 ALK 阳性肺癌。
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
3
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.非小细胞肺癌中的ALK抑制剂：克唑替尼及其他。
Clin Adv Hematol Oncol. 2014 Jul;12(7):429-39.
4
LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer.LDK378用于治疗ALK易位的非小细胞肺癌伴癌性脑膜炎的同情用药。
J Thorac Oncol. 2014 Aug;9(8):e62-3. doi: 10.1097/JTO.0000000000000174.
5
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.克唑替尼耐药的间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者中艾乐替尼针对全身疾病和脑转移的安全性和活性：一项 1/2 期研究剂量探索部分的结果。
Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.
6
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.ALK 阳性 NSCLC 患者初始疾病进展后继续使用克唑替尼抑制 ALK 带来的临床获益。
Ann Oncol. 2014 Feb;25(2):415-22. doi: 10.1093/annonc/mdt572.
7
Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.克唑替尼治疗ALK重排转移性非小细胞肺癌脑转移的有效给药方案。
J Thorac Oncol. 2013 Dec;8(12):e112-3. doi: 10.1097/JTO.0000000000000038.
8
The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.中枢神经系统作为 ALK 阳性非小细胞肺癌的庇护所。
J Thorac Oncol. 2013 Dec;8(12):1570-3. doi: 10.1097/JTO.0000000000000029.
9
High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.高剂量克唑替尼用于治疗对标准剂量克唑替尼难治的脑转移瘤。
J Thorac Oncol. 2013 Sep;8(9):e85-6. doi: 10.1097/JTO.0b013e31829cebbb.
10
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.

艾乐替尼在一名克唑替尼治疗进展且伴有弥漫性软脑膜癌病的ALK阳性非小细胞肺癌患者中诱导出持久（>15个月）的完全缓解。

Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

作者信息

Ou Sai-Hong Ignatius, Sommers Karen R, Azada Michele C, Garon Edward B

机构信息

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California, USA.

Jonsson Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA.

出版信息

Oncologist. 2015 Feb;20(2):224-6. doi: 10.1634/theoncologist.2014-0309. Epub 2015 Jan 7.

DOI:10.1634/theoncologist.2014-0309
PMID:25568147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4319629/
Abstract

This report describes a patient with -rearranged non-small cell lung cancer who developed diffuse leptomeningeal carcinomatosis as the only “site” of progression after a prolonged response to crizotinib and who has been treated successfully with a second-generation ALK inhibitor alone for >15 months.

摘要

本报告描述了一名患有重排非小细胞肺癌的患者，该患者在对克唑替尼产生长时间反应后，出现弥漫性软脑膜癌病作为唯一的进展“部位”，并且仅使用第二代ALK抑制剂成功治疗了超过15个月。